GSK Secures Non-Exclusive License to Elsie Biotechnologies Oligonucleotide Research Project

GSK, a leading pharmaceutical and healthcare firm, has opted to secure a non-exclusive license to Elsie Biotechnologies oligonucleotide research project.  

Oligonucleotides are short sequences of nucleotides used in molecular biology for tasks like DNA synthesis and genetic testing.  

In July of last year, GSK and Elsie Biotechnologies partnered to analyse the risks, distribution, and effectiveness of oligonucleotides.  

The collaboration utilised GSK’s proficiency in DNA-encoded library devices and Elsie’s drug research abilities.  

Kevin Green, the Operations Director at Elsie Biotechnologies, stated, “We are pleased that GSK has elected to license our platform technology following the research collaboration.”  

Green went on to add, “GSK is a great innovator in the field of oligonucleotide therapeutics, and this license validates the potential of our discovery platform, which we believe can power next-generation RNA medicines optimised for safety, activity, and delivery.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.